Literature DB >> 31235559

Treatment of Multidrug-Resistant Vancomycin-Resistant Enterococcus faecium Hardware-Associated Vertebral Osteomyelitis with Oritavancin plus Ampicillin.

Samira Dahesh1, Brian Wong2, Victor Nizet1,3, George Sakoulas4,5, Truc T Tran6,7, Samuel L Aitken8,9.   

Abstract

Weekly oritavancin plus ampicillin continuous infusion combination therapy was used to successfully treat a deep spine vancomycin-resistant Enterococcus faecium infection associated with hardware. Checkerboard and time-kill assays confirmed synergy between these two antibiotics. Further synergies of oritavancin and ampicillin with rifampin or the endogenous human antimicrobial peptide cathelicidin LL-37 were demonstrated.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  ampicillin; oritavancin; vancomycin-resistant Enterococcus faeciumzzm321990

Year:  2019        PMID： 31235559      PMCID： PMC6591586          DOI： 10.1128/AAC.02622-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

1.  Cathelicidin LL-37 peptide regulates endothelial cell stiffness and endothelial barrier permeability.

Authors:  Fitzroy J Byfield; Qi Wen; Katarzyna Leszczynska; Alina Kulakowska; Zbigniew Namiot; Paul A Janmey; Robert Bucki
Journal:  Am J Physiol Cell Physiol       Date:  2010-10-13       Impact factor: 4.249

2.  Synergy tests by E test and checkerboard methods of antimicrobial combinations against Brucella melitensis.

Authors:  Gani Orhan; Aysen Bayram; Yasemin Zer; Iclal Balci
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

3.  Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test.

Authors:  R L White; D S Burgess; M Manduru; J A Bosso
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

4.  Comparative Pharmacodynamics of Single-Dose Oritavancin and Daily High-Dose Daptomycin Regimens against Vancomycin-Resistant Enterococcus faecium Isolates in an In Vitro Pharmacokinetic/Pharmacodynamic Model of Infection.

Authors:  Adam Belley; David Lalonde-Séguin; Francis F Arhin; Greg Moeck
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

5.  Oritavancin activity against vancomycin-susceptible and vancomycin-resistant Enterococci with molecularly characterized glycopeptide resistance genes recovered from bacteremic patients, 2009-2010.

Authors:  Rodrigo E Mendes; Leah N Woosley; David J Farrell; Helio S Sader; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2011-12-19       Impact factor: 5.191

6.  Efficacy, safety and pharmacokinetics of tedizolid versus linezolid in patients with skin and soft tissue infections in Japan - Results of a randomised, multicentre phase 3 study.

Authors:  Hiroshige Mikamo; Yoshio Takesue; Yuji Iwamoto; Takahiko Tanigawa; Masaharu Kato; Yoko Tanimura; Shigeru Kohno
Journal:  J Infect Chemother       Date:  2018-03-09       Impact factor: 2.211

7.  Ampicillin enhances daptomycin- and cationic host defense peptide-mediated killing of ampicillin- and vancomycin-resistant Enterococcus faecium.

Authors:  George Sakoulas; Arnold S Bayer; Joseph Pogliano; Brian T Tsuji; Soo-Jin Yang; Nagendra N Mishra; Victor Nizet; Michael R Yeaman; Pamela A Moise
Journal:  Antimicrob Agents Chemother       Date:  2011-11-28       Impact factor: 5.191

8.  Lack of neuropathological changes in rats administered tedizolid phosphate for nine months.

Authors:  Michael J Schlosser; Hiromi Hosako; Ann Radovsky; Mark T Butt; Dragomir Draganov; Jenifer Vija; Frederick Oleson
Journal:  Antimicrob Agents Chemother       Date:  2014-11-10       Impact factor: 5.191

9.  In vitro activity of oritavancin alone or in combination against vancomycin-susceptible and -resistant enterococci.

Authors:  T Wu; K Meyer; A T Harrington; L H Danziger; E Wenzler
Journal:  J Antimicrob Chemother       Date:  2019-05-01       Impact factor: 5.790

10.  Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.

Authors:  Jordan R Smith; Juwon Yim; Animesh Raut; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191
View more
  4 in total

1.  Continued Dosing of Oritavancin for Complicated Gram-Positive Infections.

Authors:  Jodi Meyer; Paul Lata; Susanne Barnett
Journal:  Fed Pract       Date:  2020-11

Review 2.  New Perspectives on Antimicrobial Agents: Long-Acting Lipoglycopeptides.

Authors:  Truc T Tran; Sara Gomez Villegas; Samuel L Aitken; Susan M Butler-Wu; Alex Soriano; Brian J Werth; Jose M Munita
Journal:  Antimicrob Agents Chemother       Date:  2022-04-27       Impact factor: 5.938

3.  The CHROME Study, a Real-world Experience of Single- and Multiple-Dose Oritavancin for Treatment of Gram-Positive Infections.

Authors:  Mark Redell; Miguel Sierra-Hoffman; Maha Assi; Markian Bochan; David Chansolme; Anurag Gandhi; Kathleen Sheridan; Ivan Soosaipillai; Thomas Walsh; Jill Massey
Journal:  Open Forum Infect Dis       Date:  2019-11-04       Impact factor: 3.835

Review 4.  The Potential of Human Peptide LL-37 as an Antimicrobial and Anti-Biofilm Agent.

Authors:  Kylen E Ridyard; Joerg Overhage
Journal:  Antibiotics (Basel)       Date:  2021-05-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.